LABWORKS LIMS Acquired By PerkinElmer
News May 13, 2016
Labworks, LLC has announced that it has acquired the LABWORKS LIMS product line from PerkinElmer Health Sciences. The LABWORKS LIMS product line, which has a 25-year history of LIMS excellence, was purchased by Labworks, LLC, which is comprised of seasoned software executives and many previous PerkinElmer/LABWORKS employees, many of whom have over 20 years of experience supporting LABWORKS LIMS and its 300+ customer base.
With a focus on customer satisfaction and product innovation, Labworks LLC has already drastically increased the size of its support and engineering teams, with the average employee having at least 10 years of LABWORKS and LIMS experience. “We are heavily committed to customer service and product innovation and we have assembled a team that is well positioned to drastically improve the experience of our hundreds of loyal customers,” says Lane Franks, CEO of Labworks, LLC.
To ensure the success of the new company, a new management team has been created that, includes, among others, Paul Fjeldsted as the CTO and Lane Franks as the CEO. “I am passionate about the LABWORKS product line and our customer base. When I saw PerkinElmer begin to move in a different direction, I wanted an opportunity to create a high performance team that I knew could provide more for our customers,” comments Paul Fjeldsted. Paul continues, “Lane and I formed a vision, recruited an 'A team,' and presented a customer focused plan that showed our customer commitment and LIMS ability. PerkinElmer agreed with our vision and the new Labworks was born.”
Paul Fjeldsted has a 30 year career in technology spanning from the early Hewlett Packard Mass Spectrometer training days to developing software for Aligent’s Chemstation solution. In the mid '90s, Paul became the lead developer for PerkinElmer’s LABWORKS LIMS solution. Since Paul has over 20 years’ experience at PerkinElmer developing their LIMS software, it was a natural progression for him to take LABWORKS independent and provide the customer with a better experience.
Lane Franks joins Paul Fjeldsted on this journey to offer the best LIMS solution on the market as CEO of Labworks. Lane Franks has over 25 years of executive management, operations and product management experience in the high-tech industry, working for industry giants such as Accenture, Novel, Yahoo, Overture, Siebel, Nokia and others.
“I’ve always respected Paul and as I learned more and more about the strong LABWORKS customer base and solid technology, I knew we had the critical components needed to be successful. Now that we have formed a large and experienced team, we have what is needed to take LABWORKS to the next level. Together, Paul and I have begun making improvements to the company and its products by creating new and requested features for the software and bringing on new talent to drive continuity to services and support.”
Labworks has already created new features for its LABWORKS solution with its next release, v6.6, scheduled for early summer. The new features include, among others, a new instrument interface option, “NGII,” that will allow users to quickly and easily integrate with their instruments, as well as creating Scan Daemon and Process Scheduler services for greater performance and reliability. In the near-term, Labworks, LLC will focus their development resources on migrating functionality from the local client to web based functions and eventually to an “as-a-Service” model for customers that prefer such a model.
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Deceased Data: Should Your Online Remains Be Treated Like Physical Remains?News
In 2018, your death doesn't just leave behind a body. It leaves behind a huge online footprint - your digital remains. A new study asks whether these remains should be treated and respected as a corpse would, and whether museums may provide a blueprint for the preservation process.READ MORE